[go: up one dir, main page]

BR9813114A - Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf - Google Patents

Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf

Info

Publication number
BR9813114A
BR9813114A BR9813114-1A BR9813114A BR9813114A BR 9813114 A BR9813114 A BR 9813114A BR 9813114 A BR9813114 A BR 9813114A BR 9813114 A BR9813114 A BR 9813114A
Authority
BR
Brazil
Prior art keywords
tnf antagonists
sepsis
treated
commercial package
patient suffering
Prior art date
Application number
BR9813114-1A
Other languages
English (en)
Inventor
Hartmut Kupper
Martin Kaul
Juergen Eiselstein
Lothar Daum
Joachim Kempeni
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9813114A publication Critical patent/BR9813114A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE ANTAGONISTAS TNF PARA PRODUZIR MEDICAMENTOS, PACOTE COMERCIAL, E, PROCESSO PARA ESTABELECER SE UM PACIENTE QUE ESTEJA SOFRENDO DE SéPSIS DEVA SER TRATADO COM OS ANTAGONISTAS TNF". A invenção se relaciona com a aplicação de antagonistas TNF para produzir medicamentos para o tratamento de doenças sépticas caracterizadas por um bruto crescente do nível de interleucina-6 no soro durante um intervalo de medição de no mínimo trinta minutos.
BR9813114-1A 1997-10-23 1998-10-15 Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf BR9813114A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746868A DE19746868A1 (de) 1997-10-23 1997-10-23 Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
PCT/EP1998/006545 WO1999021582A2 (de) 1997-10-23 1998-10-15 Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen

Publications (1)

Publication Number Publication Date
BR9813114A true BR9813114A (pt) 2000-08-15

Family

ID=7846420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813114-1A BR9813114A (pt) 1997-10-23 1998-10-15 Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf

Country Status (13)

Country Link
EP (1) EP1024831A2 (pt)
JP (1) JP2001521009A (pt)
KR (1) KR20010024549A (pt)
CN (1) CN1163272C (pt)
AU (1) AU756167B2 (pt)
BR (1) BR9813114A (pt)
CA (1) CA2306790A1 (pt)
DE (1) DE19746868A1 (pt)
HU (1) HUP0100105A3 (pt)
IL (1) IL135083A0 (pt)
NO (1) NO20001894D0 (pt)
WO (1) WO1999021582A2 (pt)
ZA (1) ZA989615B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2012007845A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
WO2012007839A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EP2415461B1 (en) * 2010-07-24 2012-10-31 Roche Diagnostics GmbH Stabilization of interleukin 6 in serum based solutions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
CN1163272C (zh) 2004-08-25
AU1228499A (en) 1999-05-17
EP1024831A2 (de) 2000-08-09
CN1277556A (zh) 2000-12-20
NO20001894L (no) 2000-04-12
ZA989615B (en) 2000-04-20
HUP0100105A2 (hu) 2001-05-28
HUP0100105A3 (en) 2003-08-28
JP2001521009A (ja) 2001-11-06
WO1999021582A3 (de) 1999-07-15
WO1999021582A2 (de) 1999-05-06
NO20001894D0 (no) 2000-04-12
CA2306790A1 (en) 1999-05-06
KR20010024549A (ko) 2001-03-26
IL135083A0 (en) 2001-05-20
DE19746868A1 (de) 1999-04-29
AU756167B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
UA42779C2 (uk) Фармацевтично стійкий препарат оксалату платини для парентерального застосування
ATE239482T1 (de) Neue arzneiformulierung
BR9706835A (pt) Hidrogel de copolìmero de acrilamida implantável para usos terapêuticos
ATE310501T1 (de) Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
PT998288E (pt) Composicoes contendo capsaicina ou analogos de capsaicina e um anestesico local
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
DE60113815D1 (de) Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren
KR920700667A (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
BR9813114A (pt) Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE60214527D1 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
DE69821498D1 (de) Verwendung von amifostin
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
EP0305277A3 (fr) Application de l'amino-2 trifluoro-méthoxy-6 benzothiazole pour obtenir un médicament destiné au traitement des troubles du sommeil et de la dépression
ATE67410T1 (de) Methode zur behandlung der antidiurese.
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
TR199801798T2 (xx) Otizm tedavisi.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH (DE)

B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.